Alpha-Beta Arteether

Alpha-Beta Arteether is a combination medication used for the treatment of malaria, a parasitic infection transmitted through the bite of an infected mosquito. The medication works by targeting the malarial parasite’s protein synthesis, effectively stopping its growth and reproduction in the red blood cells.
Alpha-Beta Arteether consists of two active ingredients: alpha-difluoromethylornithine (DFMO) and beta-difluoromethylornithine (DFMO). Both compounds are inhibitors of ornithine decarboxylase, an enzyme involved in the biosynthesis of polyamines, which are essential for the growth and survival of the malaria-causing parasite, Plasmodium species.
This combination medication is particularly effective against chloroquine-resistant strains of the parasite, making it a valuable tool in the fight against malaria in regions where drug-resistant strains are prevalent. The World Health Organization (WHO) recommends Alpha-Beta Arteether as a first-line treatment for malaria in certain regions due to its efficacy and safety profile.
Alpha-Beta Arteether is typically administered orally and should be taken under the guidance of a healthcare professional. Follow the prescribed dosage and complete the full course of treatment, even if symptoms subside, to ensure the effective eradication of the parasite from the body.